Download App

Log in to access Online Inquiry
Company Overview More
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
CEO: Conterno, Enrique A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > FGEN FibroGen > Detailed Quotes

FGEN FibroGen

8.660+0.140+1.64%
Close 05/25 20:00 ET
8.66000.00%
Post Mkt Price 05/25 16:00 ET
High
8.710
Open
8.470
Turnover
18.20M
Low
8.250
Pre Close
8.520
Volume
2.17M
Market Cap
807.96M
P/E(TTM)
Loss
52wk High
30.125
Shares
93.30M
P/E(Static)
Loss
52wk Low
7.810
Float Cap
702.26M
Bid/Ask %
0.00%
Historical High
68.550
Shs Float
81.09M
Volume Ratio
1.90
Historical Low
7.810
Dividend TTM
--
Div Yield TTM
1000
P/B
5.11
Dividend LFY
--
Div Yield LFY
11547.34%
Turnover Ratio
2.68%
Amplitude
5.40%
Avg Price
8.382
Lot Size
1
Float Cap
702.26M
Bid/Ask %
0.00%
Historical High
68.550
Shs Float
81.09M
Volume Ratio
1.90
Historical Low
7.810
Dividend TTM
--
P/B
5.11
Dividend LFY
--
Turnover Ratio
2.68%
Amplitude
5.40%
Avg Price
8.382
Lot Size
1
Price Forecast

No Data

News

Comment